Amwell Reports Earnings November 3, 2026 After The Close: The Turnaround Gets a Checkup -( $AMWL )

Smaller Losses, Substantial Cash and a More Interesting Business

Amwell (NYSE: AMWL) heads into its third-quarter earnings announcement with a proposition worth watching: a technology-enabled healthcare business approaching adjusted operating breakeven, supported by nearly $196 million in cash and equivalents and a growing emphasis on subscription revenue. Its second-quarter results suggest that the most compelling part of the story may no longer be how many virtual appointments it can facilitate, but how efficiently it can run the infrastructure behind them. The immediate catalyst arrives November 3, 2026, when Amwell is scheduled to report third-quarter results after the market closes, followed by a management webcast at 5 p.m. Eastern. This is an earnings preview, not a report of third-quarter results. For many following AMWL stock, the bullish thesis centers on execution: tighter expenses, a substantial liquidity cushion, broader clinical capabilities and the possibility that a long-running technology investment cycle is beginning to produce a more disciplined financial model. Healthcare software need not win a beauty contest. It does, however, eventually need to pay its own bills.

Amwell’s Financial Turnaround Is Becoming More Tangible

Amwell’s second-quarter numbers offered evidence that its financial reset is moving beyond presentation slides. For the quarter ended June 30, 2026, the company reported:

• Revenue of $52.0 million, at the upper end of its previously issued quarterly guidance.
• Subscription revenue of $25.7 million.
• Amwell Medical Group visit revenue of $24.4 million.
• Reported gross margin of 53%.
• A net loss of $9.6 million, compared with $19.5 million a year earlier.
• An adjusted EBITDA loss of approximately $1.2 million, compared with $4.7 million a year earlier and $3.1 million in the first quarter.[sec]

The particularly encouraging development is the narrowing loss profile despite a smaller revenue base. Second-quarter revenue declined from $70.9 million in the comparable 2025 period, but total costs and operating expenses fell from $91.3 million to $61.6 million. The operating loss narrowed from $20.4 million to $9.6 million. That is not yet a growth victory. It is evidence of a business becoming less expensive to operate. The distinction matters. A turnaround can begin with better economics before it produces renewed expansion. For Amwell, the next challenge is to demonstrate that a leaner cost structure can support durable customer relationships and, ultimately, a healthier revenue trajectory.

Subscription Revenue Gives the Story a Different Center of Gravity

Amwell’s $25.7 million in second-quarter subscription revenue represented nearly half of total revenue. Management highlighted that mix as part of its argument that the company is better positioned for technology-enabled and AI-powered care. The strategic appeal is straightforward. A platform embedded in a health plan’s or health system’s workflow can have a different commercial role from a service used only when someone needs an occasional online appointment. Amwell describes its offering as a unified platform connecting payers, providers and consumers across telehealth transactions. Its platform materials emphasize bringing multiple care functions into a more coherent healthcare experience. That is the more interesting bullish interpretation of AMWL: not merely a destination for virtual visits, but software and services that healthcare organizations can use to deliver their own digital care programs. Amwell’s first-quarter Form 10-Q explicitly describes a business that enables clients to develop and distribute virtual care under their own brands. A patient may never notice the infrastructure provider. In enterprise software, anonymity can be perfectly respectable if the customer keeps renewing.

Converge Expands the Opportunity Beyond the Video Visit

Amwell’s Converge platform was designed around an open architecture and a single code base, with room for the company’s own products, clinical programs, devices and third-party applications. That design establishes the foundation for a broader digital-care business rather than a collection of disconnected video encounters. The company has also announced built-in electronic health record integration capabilities for Converge. Such integration supports its effort to make virtual care part of existing clinical workflows instead of another separate system clinicians must manage. Amwell’s more recent platform materials continue to emphasize a scalable, extensible design that allows health plans to engage members and support additional capabilities. These materials describe product positioning, not proof of future sales, but they help explain the commercial ambition behind the platform. The potential advantage is breadth. If a healthcare organization can connect more care functions through one platform, Amwell has an opportunity to compete on usefulness across the care journey rather than on the convenience of a single appointment. That opportunity still requires sales execution. Architecture does not sign contracts, even when the architecture is excellent.

Clinical Partnerships Add Practical Substance

The platform thesis becomes more persuasive when its capabilities extend into ordinary clinical work. Amwell’s expanded relationship with Health Gorilla introduced diagnostic laboratory ordering capabilities within Converge. The announced integration allows providers to place electronic lab orders, review results and automate processes within the platform. That is an important strategic direction: making a virtual encounter more clinically actionable. A consultation becomes more useful when the clinician can move naturally from discussion to diagnostic follow-through. Amwell also added Hello Heart to its clinical programs portfolio in October 2024. The partnership brought a preventive heart-health solution into the company’s broader ecosystem, which Amwell positioned as a unified entry point for health plans, employers and members seeking access to multiple digital-care programs. Separately, Amwell reported that Converge had been recognized for breadth of capabilities and care settings in a July 2023 KLAS Research report. In its May 2024 account of that recognition, the company said more than one million patient visits had been completed on Converge during its first 18 months. Those are historical platform-development indicators, not current-quarter operating statistics. Together, these developments support a more substantive thesis than simply “telehealth will grow.” Amwell is attempting to make its platform useful across more of the work that surrounds a clinical encounter.

Nearly $196 Million in Cash Gives Management Room to Execute

Amwell ended June 2026 with $195.9 million in cash and cash equivalents, plus approximately $795,000 in restricted cash. Management also stated that the company had no debt. That balance-sheet position gives the turnaround an important resource: time to execute without the immediate burden of servicing borrowings. Cash-flow performance also improved. Amwell reported $9.7 million in cash provided by operating activities during the first half of 2026, compared with $29.8 million used in the first half of 2025. The composition deserves attention, however. The 2026 operating cash-flow figure benefited from increases in accrued expenses and other current liabilities, as well as deferred revenue. It should not be treated as proof that the business has already established a durable, recurring cash-generation pattern. Management’s stated objective remained positive operating cash flow in the fourth quarter of 2026. Achieving that target, and then sustaining it, would strengthen the case that Amwell’s financial transformation has staying power. For many assessing a turnaround, the combination of liquidity and smaller losses is more useful than either one alone. Cash buys time. Better economics make that time more valuable.

The Defense Health Agency Could Be a Meaningful Catalyst

One of the most consequential items in Amwell’s second-quarter announcement concerned the Defense Health Agency. Chairman and Chief Executive Dr. Ido Schoenberg said the agency intended to make Amwell a prime contractor, describing the development as an endorsement of the company’s platform and personnel. That was management’s characterization of the agency’s intent, not confirmation in the release of a completed, fully deployed enterprise-wide arrangemen. The potential significance is clear: a more direct contracting role could strengthen Amwell’s position in an important customer relationship. But the contractual details are essential. The same SEC-filed release identified both broader DHA deployment and continuation of the relationship beyond the third quarter of 2026 on comparable financial terms as uncertainties. Accordingly, the November earnings discussion offers an opportunity to assess whether that potential is becoming a more concrete commercial outcome. Government contracting can be attractive. It also has a well-developed appreciation for paperwork.

What Many Should Watch in Amwell’s Q3 2026 Earnings

Amwell entered the announcement with previously issued third-quarter guidance calling for revenue of $46 million to $48 million and an adjusted EBITDA loss of $3 million to $5 million. That outlook anticipated a wider adjusted loss than the company reported in the second quarter. A careful reading therefore measures performance against the stated quarterly plan, rather than assuming that every quarter must improve sequentially. The most useful checkpoints are:

1. Revenue delivery. Results within or above the previously issued range would support confidence in management’s near-term forecasting.
2. Subscription performance. The question is not simply whether subscriptions remain a large percentage of revenue, but whether the underlying subscription business demonstrates resilience.
3. Cash-flow durability. Working-capital movements should be considered alongside progress toward management’s fourth-quarter operating cash-flow objective.
4. DHA contract visibility. Greater clarity on contracting status, continuity and financial terms would help many judge the quality of the opportunity.
5. Full-year guidance. In August, Amwell raised the lower end of its 2026 revenue outlook to $200 million from $195 million, maintained the upper end at $205 million, and improved its adjusted EBITDA outlook to a loss of $7 million to $9 million from a previously expected loss of $12 million to $16 million.

Adjusted EBITDA remains a non-GAAP measure, not a substitute for net income or operating cash flow. Amwell’s reconciliation excludes items including stock-based compensation, depreciation and amortization, and certain transformation costs. The closer the company moves toward adjusted breakeven, the more important those distinctions become.

The Bullish Case Is Stronger When It Respects the Remaining Work

Amwell still has material work ahead. Revenue contracted year over year in the second quarter, and customer concentration remains relevant. Its first-quarter Form 10-Q disclosed that two clients accounted for 42% and 16% of quarterly revenue, respectively. Those figures make customer retention, contract continuity and platform adoption central to the outlook. A successful turnaround requires more than reducing expenses. It requires protecting the relationships that make the platform economically valuable. Still, the foundation of a constructive AMWL story is identifiable: sharply smaller losses, subscription revenue approaching half of sales, a substantial cash position and an expanding set of clinical capabilities. The potential opportunity is a change in how the business is understood. If Amwell can translate its platform investments and financial discipline into sustainable cash generation, many may begin evaluating it less as a virtual-visit provider searching for its next chapter and more as an enterprise healthcare platform proving its operating model. That would be a welcome development for a company whose most persuasive new feature may turn out to be financial restraint.

The Sources

1. Amwell: Third-Quarter 2026 Earnings Announcement and Webcast Schedule
2. SEC.gov: Amwell Second-Quarter 2026 Results, Exhibit 99.1, Including Financial Statements and Non-GAAP Reconciliation
3. SEC.gov: American Well Corporation Form 10-Q for the Quarter Ended March 31, 2026
4. Amwell: Second-Quarter 2026 Results and Updated Financial Outlook
5. Amwell: The Amwell Platform
6. Amwell: Next-Generation Converge Telehealth Platform and Open Architecture
7. Amwell: Converge Platform and Electronic Health Record Integration Capabilities
8. Amwell and Health Gorilla: Expanded Digital Diagnostic Lab Ordering
9. Amwell: Hello Heart Joins the Clinical Programs Portfolio
10. Amwell: Report on KLAS Virtual Health Recognition and Historical Converge Adoption
11. Amwell: Converge Platform Brochure